Indeed, some folk are comfortable with fixed term deposits or yield investing, some are as comfortable as a value or growth investor, each to their own.
I would never advocate being entirely in one stock, setting diversification limits is everything if you are a growth investor or if one holds growth stocks.
As far as Edison go, they offer information not available from other sources as they have the opportunity to question and critique Pacific Edge, just as they do so for thousands of other companies globally.
They also have specialist expert biotech sector analysts based in the UK and US who have authored the reports, Kathrine Genis, Emma Ulker and Dr Mick Cooper. Not something readily available to the local brokers.
I’ve been advised by Pacific Edge that Edison will be their primary vehicle for providing shareholder information.
I think most shareholders and prospective shareholders do probably appreciate that effort, the cost of Edison reports, as I understand is circa $60k per throw, not something Pacific Edge have to provide, or a cost they have to incur.
Initiating Edison report here, updates available on their website